Form 4: Quest Diagnostics Director Acquires Shares

Quest Diagnostics Director Luis Diaz acquired 1,142 shares of common stock.

Summary

• Luis Diaz, a Director at Quest Diagnostics, acquired 1,142 shares of common stock on May 20, 2026.
• The acquisition was made at a price of $0, indicating it was likely an award or grant.
• Following this transaction, Mr. Diaz beneficially owns 5,196 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine stock award to a director rather than a significant new investment or divestment.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of 1,142 shares at $0 suggests a stock award, which is a common form of executive compensation.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by directors, are common within the healthcare diagnostics industry as a component of executive compensation and a signal of management's commitment to the company's performance.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, but the transaction itself is a routine award and unlikely to have a significant immediate impact on share price.

Key Dates

Keywords

Quest Diagnostics, DGX, Form 4, Insider Trading, Director, Stock Acquisition, Beneficial Ownership